Bulletin
Investor Alert

Intellia Therapeutics Inc.

NAS: NTLA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Intellia Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Jun 27, 2022, 5:45 p.m.

NTLA
/zigman2/quotes/207821052/composite

$

53.50

Change

+0.10 +0.19%

Volume

Volume 13,275

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Today's close

$ 53.41

$ 53.40

Change

-0.01 -0.02%

Day low

Day high

$51.07

$54.55

Open

52 week low

52 week high

$37.08

$202.73

Open

Company Description

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in t...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

253.61

Price to Book Ratio

8.47

Enterprise Value to EBITDA

-12.17

Enterprise Value to Sales

83.88

Efficiency

Total Asset Turnover

0.03

Liquidity

Current Ratio

6.11

Quick Ratio

6.11

Cash Ratio

5.95

Profitability

Gross Margin

79.15

Operating Margin

-810.37

Pretax Margin

-810.49

Net Margin

-810.49

Return on Assets

-27.19

Return on Equity

-34.18

Return on Total Capital

-31.87

Capital Structure

Total Debt to Total Assets

5.72

Officers and Executives

Name Age Officer Since Title
Dr. John M. Leonard 63 2014 Director & Chief Medical Officer
Mr. Glenn Goddard 48 2018 Executive VP, Chief Financial & Accounting Officer
Dr. Laura Sepp-Lorenzino 60 2019 Chief Scientific Officer & Executive VP
Dr. Eliana Clark - - Senior Vice President-Technical Operations
Dr. David Lebwohl - 2020 Chief Medical Officer & Executive Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/14/2022 Fred Ehrenkranz Cohen
Director 		5,197   Award at $0 per share. 0
06/14/2022 Caroline D. Dorsa
Director 		5,197   Award at $0 per share. 0
06/14/2022 Georgia Keresty
Director 		5,197   Award at $0 per share. 0
06/14/2022 Muna Bhanji
Director 		2,014   Award at $0 per share. 0
06/14/2022 John Francis Crowley
Director 		5,197   Award at $0 per share. 0
06/14/2022 Jean-Francois B. Formela
Director 		5,197   Award at $0 per share. 0
06/14/2022 Frank A. G. M. Verwiel
Director 		5,197   Award at $0 per share. 0
06/14/2022 Jesse L. Goodman
Director 		5,197   Award at $0 per share. 0
04/28/2022 Muna Bhanji
Director 		7,954   Award at $0 per share. 0
03/01/2022 John M. Leonard
President and CEO; Director 		40,990   Award at $0 per share. 0
03/01/2022 David Lebwohl
EVP, Chief Medical Officer 		13,816   Award at $0 per share. 0
03/01/2022 Eliana Clark
EVP, Chief Technical Officer 		10,527   Award at $0 per share. 0
03/01/2022 Glenn Goddard
EVP, Chief Financial Officer 		12,720   Award at $0 per share. 0
01/03/2022 Derek Hicks
EVP, Chief Business Officer 		19,118   Award at $0 per share. 0
01/01/2022 John M. Leonard
President and CEO; Director 		2,493   Disposition at $112.26 per share. 279,864
01/01/2022 David Lebwohl
EVP, Chief Medical Officer 		1,051   Disposition at $112.24 per share. 117,964
01/01/2022 Glenn Goddard
EVP, Chief Financial Officer 		1,013   Disposition at $112.24 per share. 113,699
01/01/2022 John M. Leonard
President and CEO; Director 		7,848   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2022 David Lebwohl
EVP, Chief Medical Officer 		3,187   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2022 Glenn Goddard
EVP, Chief Financial Officer 		3,062   Derivative/Non-derivative trans. at $0 per share. 0
11/05/2021 David Lebwohl
EVP, Chief Medical Officer 		200   Disposition at $135.34 per share. 27,068
11/05/2021 David Lebwohl
EVP, Chief Medical Officer 		548   Disposition at $134.07 per share. 73,470
11/05/2021 David Lebwohl
EVP, Chief Medical Officer 		452   Disposition at $132.62 per share. 59,944
11/05/2021 David Lebwohl
EVP, Chief Medical Officer 		1,200   Disposition at $131.71 per share. 158,052
11/05/2021 David Lebwohl
EVP, Chief Medical Officer 		2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
10/14/2021 David Lebwohl
EVP, Chief Medical Officer 		250   Disposition at $130.47 per share. 32,617
10/14/2021 David Lebwohl
EVP, Chief Medical Officer 		525   Disposition at $129.83 per share. 68,160
10/14/2021 David Lebwohl
EVP, Chief Medical Officer 		225   Disposition at $129.01 per share. 29,027
10/14/2021 David Lebwohl
EVP, Chief Medical Officer 		849   Disposition at $127.81 per share. 108,510
10/14/2021 David Lebwohl
EVP, Chief Medical Officer 		551   Disposition at $126.92 per share. 69,932
10/14/2021 David Lebwohl
EVP, Chief Medical Officer 		2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
10/11/2021 John Francis Crowley
Director 		2,500   Disposition at $119.55 per share. 298,875
10/11/2021 John Francis Crowley
Director 		2,500   Derivative/Non-derivative trans. at $18.83 per share. 47,075
10/05/2021 John Francis Crowley
Director 		200   Disposition at $132.84 per share. 26,568
10/05/2021 John Francis Crowley
Director 		1,846   Disposition at $131.74 per share. 243,192
10/05/2021 John Francis Crowley
Director 		3,759   Disposition at $130.92 per share. 492,128
10/05/2021 John Francis Crowley
Director 		2,915   Disposition at $129.88 per share. 378,600
10/05/2021 John Francis Crowley
Director 		1,280   Disposition at $128.83 per share. 164,902
10/05/2021 John Francis Crowley
Director 		10,000   Derivative/Non-derivative trans. at $18.83 per share. 188,300
09/24/2021 David Lebwohl
EVP, Chief Medical Officer 		7,923   Derivative/Non-derivative trans. at $12.62 per share. 99,988
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    4:25 p.m. June 23, 2022

    - Barron's Online

  2. Intellia Therapeutics started at market perform with $54 stock price target at BMO Capital

    12:22 p.m. June 17, 2022

    - Tomi Kilgore

  6. Intellia Therapeutics upgraded to outperform from perform at Oppenheimer

    8:28 a.m. Feb. 7, 2022

    - Tomi Kilgore

  9. Beam Gets FDA Nod for First Gene-Editing Trial

    9:10 a.m. Nov. 9, 2021

    - Barron's Online

  10. Prime Is the Newest Gene Editing, and It's Getting Better

    7:11 p.m. Oct. 20, 2021

    - Barron's Online

  12. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    7:37 a.m. Sept. 27, 2021

    - Barron's Online

  13. Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus

    7:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  14. Intellia Therapeutics stock price target raised to $190 from $90 at Evercore ISI

    5:58 a.m. Aug. 6, 2021

    - Tomi Kilgore

  15. The Best and Worst Biopharma Stock Performers So Far in 2021

    11:32 a.m. June 30, 2021

    - Barron's Online

  16. Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform

    7:37 a.m. June 29, 2021

    - Tonya Garcia

  18. Intellia Therapeutics price target doubled to $160 from $80 at Truist Securities, stock maintained at buy

    11:24 a.m. June 28, 2021

    - Tonya Garcia

  19. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    9:21 a.m. June 30, 2021

    - Barron's Online

  20. First In-Vivo Gene Editing Data Look Good for Intellia

    8:40 a.m. June 28, 2021

    - Barron's Online

  21. Loading more headlines...
/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  5. 5 Health Care Stocks Cathie Wood Favors

    3:07 p.m. June 9, 2022

    - GuruFocus.com

  7. Graphite Bio: Selling For Much Less Than Net Cash

    12:14 p.m. May 25, 2022

    - Seeking Alpha

  8. The Correction In Biopharmaceutical Stocks Is Likely Over

    12:51 a.m. May 18, 2022

    - Seeking Alpha

  9. Why Editas Medicine's Shares Fell 28.9% This Week

    11:52 a.m. May 13, 2022

    - Motley Fool

  10. Intellia Therapeutics: Several Catalysts Expected For H2 2022

    5:59 p.m. May 12, 2022

    - Seeking Alpha

  11. Top 5 1st Quarter Trades of Atlas Venture Associates IX, LLC

    5:00 p.m. May 12, 2022

    - GuruFocus.com

  12. ARKG: Don't Expect Any Favorable Return In Short Or Medium Term

    10:06 a.m. May 11, 2022

    - Seeking Alpha

  17. 10-Q: INTELLIA THERAPEUTICS, INC.

    4:13 p.m. May 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  21. Loading more headlines...

At a Glance

Intellia Therapeutics, Inc.

40 Erie Street

Suite 130

Cambridge, Massachusetts 02139

Phone

1 8572856200

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$33.05M

Net Income

$-267.89M

Employees

485.00

Annual Report for NTLA

/news/pressrelease/company/us/ntla

Press Releases on NTLA

  3. Wednesday's ETF Movers: ARKK, XME

    1:42 p.m. June 8, 2022

    - MarketNewsVideo.com

  5. Chau Khuong Joins Catalio Capital Management as General Partner

    3:00 p.m. May 25, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.